renal injury leading to tubulointerstitial fibrosis that was stitium of mouse kidneys with unilateral ureteral obstruction. pioneered by Klahr and Purkerson [1, 2]. The UUO is an Background. Recently, we demonstrated increased oxidaexcellent model of interstitial fibrosis because it is normotive stress in the interstitium of ureteral obstructed kidneys tensive, nonproteinuric, and nonhyperlipidemic without based on the increased expression of heme oxygenase-1 and any apparent immune or toxic renal insult. The molecuimmunohistochemical detection of advanced glycation end products (AGE) in the interstitium. Antioxidant therapy may have lar and cellular mechanism(s) of interstitial fibrosis in a therapeutic potential toward interstitial fibrosis of unilateral UUO kidney is beginning to be elucidated. The mechaniureteral obstruction (UUO) kidneys. Fluvastatin is an HMGcal disturbances resulting from ureteral ligation (tension CoA reductase inhibitor and has been demonstrated to have stress) [3], hypoxia induced by a marked decline in renal an antioxidant activity in vitro. plasma flow [2], up-regulation of monocyte chemoattrac-Methods. The effects of fluvastatin on UUO kidneys from the viewpoints of antioxidant action in vivo and antifibrosis tant peptide [4], osteopontin [5], heat shock protein 47 action were studied. To investigate the antioxidant action and (HSP47) [6, 7], intercellular adhesion molecule 1 [8], its therapeutic efficacy of fluvastatin in UUO kidneys, AGE macrophage influx into the interstitium [4, 9], and proaccumulation and fibrosis in the obstructed kidneys was comduction of macrophage-derived cytokines, especially pared among vehicle-, pravastatin-, or fluvastatin-treated (10 or 40 mg/kg/day) groups.
inhibitor, as a test compound since fluvastatin is known Tissue preparation to have antioxidant activity in vitro [15] [16] [17] . Pravastatin, For morphological examination, the mice were anesanother HMG-CoA reductase inhibitor that lacks antithetized with pentobarbital, and the kidneys were peroxidant activity, was used as a control compound. fused in situ with cold phosphate-buffered saline (PBS) In the present study, we studied the effect of fluvastatin to remove circulating blood cells. The kidneys were reon the tubulointerstitial lesion of obstructed kidneys moved, sliced transversely in 2 to 3 mm thick sections, from the viewpoint of oxidative stress. Immunohistologiimmersed in a cold 4% paraformaldehyde (PFA) or 70% cal detection of advanced glycation end product (AGE) ethanol solution for 16 to 24 hours, and embedded in was performed using anti-AGE monoclonal antibody, paraffin. Four micrometer thick paraffin sections were which recognizes mainly CML, and the effects of fluvassubjected to Masson's trichrome staining. tatin and pravastatin on the accumulation of AGE were compared. HO-1 mRNA expression was also studied one
Immunohistochemical study day after ureteral ligation. We found significant amelio-Antibodies. ␣-Smooth muscle actin (␣-SMA) was idenration of interstitial fibrosis along with decreased accumutified with mouse anti-␣-SMA monoclonal antibody (1A4; lation of AGE in the interstitium of the obstructed kid-EPOS, peroxidase-conjugated; Dako, Glostrup, Denneys. HO-1 mRNA induction was blunted by fluvastatin mark). Mouse anti-AGE monoclonal antibody (4D12; treatment. These findings demonstrate the antioxidant peroxidase-conjugated) was purchased from Wako Chemactivity of fluvastatin in vivo and suggest the therapeutic value of fluvastatin in the treatment of interstitial fibrosis.
ical Company (Osaka, Japan). Paraffin sections obtained from obstructed kidneys and contralateral control kidneys were deparaffinized by METHODS xylene. All sections were incubated in a 99:1 methanol/ Experimental protocol and disease model H 2 O 2 solution for 30 minutes at room temperature to in-This study was designed to determine whether fluvasactivate the endogenous peroxidase activity, then washed tatin reduces oxidative stress in the interstitium of obin PBS for 10 minutes three times, and preincubated at structed kidneys and improves the tubulointerstitial firoom temperature in blocking solution (10% goat serum brosis of the affected kidneys. Pravastatin was used as a and 1% bovine serum albumin (BSA), 0.01% Triton control compound because it is an HMG-CoA reductase x-100) for 30 minutes. The blocking solution was then inhibitor without antioxidant activity. Two experimental blotted onto a paper, and the first antibody was applied protocols were performed. The first experiment was unto the sections. Incubation with the first antibody was dertaken as a pilot study to determine the effective dosperformed for 16 hours at 4ЊC. After removal of the first age and actual consumption of the fluvastatin. The sumantibody and three serial washes in ice-cold PBS (10 min mary of the first experiment is described in the Results each), the sections for ␣-SMA and AGE were incubated section. Based on the first experiment, the following with solution containing 0.35 mg/mL p-dimethyl aminodoses of the fluvastatin were chosen for the second experbenzaldehyde and in 50 mmol/L Tris-HCl (pH 7.6) to visiment. Mice were given a standard diet (CRF-1; Oriental ualize the peroxidase activity on the section. After coun-Yeast Co., Ltd., Tokyo, Japan) containing 0.004% (10 terstaining in methyl green, the sections were mounted. mg/kg body weight) or 0.016% (40 mg/kg body weight) test compounds from three days before (Ϫ3) the UUO As a negative control for AGE or ␣-SMA staining, noroperation to the day of sacrifice. Male B6C3 F1 mice, mal mouse serum was used instead of the anti-AGE or weighing 20 to 22 g, were used in these experiments.
␣-SMA antibody. No significant staining was observed The general procedure of the mouse UUO operation is in the sections incubated with normal mouse serum inthe same as described previously [7] . After induction of stead of the first antibody. general anesthesia by the intraperitoneal injection of pentobarbital (50 mg/kg body weight), all mice under-RNA isolation and Northern blotting went left proximal ureteral ligation. The left ureter was For RNA extraction, the kidneys were perfused in situ identified through a small suprapubic incision and was with cold PBS, were removed and snap frozen in liquid ligated with 4-0 silk at two points. Both the obstructed nitrogen, and were kept at Ϫ80ЊC until use. A whole kidand contralateral kidneys were harvested from UUO aniney was homogenized with a Polytron homogenizer (Kimals at 1 (vehicle, N ϭ 7; fluvastatin 10 mg/kg, N ϭ 8; nematica, Lucerne, Switzerland) in TRIzol reagent (3 mL fluvastatin 40 mg/kg, N ϭ 8; pravastatin, N ϭ 7), 4 (vehicle, for a whole kidney; GIBCO BRL, Gaithersburg, MD, N ϭ 7; fluvastatin 10 mg/kg, N ϭ 8; fluvastatin 40 mg/kg, USA), and the total cellular RNA was prepared by acid N ϭ 6; pravastatin, N ϭ 7), and 10 days (vehicle, N ϭ guanidinium thiocyanate-phenol-chloroform extraction 6; fluvastatin 10 mg/kg, N ϭ 8; fluvastatin 40 mg/kg, procedure according to the manufacturer's instructions N ϭ 8; pravastatin, N ϭ 7) after ureteral obstruction. [18] . Twenty micrograms of RNA were size fractionated Midcoronal sections of the kidneys were also taken for immunohistochemical labeling.
on 1% agarose-formaldehyde gel and transferred to a nylon membrane filter (Hybond Nϩ; Amersham, Bos-scope; Mitani Corporation, Fukui, Japan), and the percentage of the fibrotic area or immunostaining positive ton, MA, USA) and cross-linked by ultraviolet wave irradiation. Prehybridization of the membranes was done area relative to the whole area of the field was calculated (percentage area). Glomeruli and large vessels were not for two hours at 42ЊC in a buffer containing 5 ϫ SSPE [1 ϫ SSPE ϭ 150 mmol/L NaCl, 11 mmol/L NaH 2 PO 4 , 2 included in the microscopic fields for image analysis. The scores of the five fields of each kidney were averaged. mmol/L ethylenediaminetetraacetic acid (EDTA)], 10 ϫ Denhardt's (100 ϫ Denhardt's ϭ 2% Ficoll, 2% polyvi-
The scores of six separate animals were then averaged. nylpyrroridone, 2% BSA), 0.5% sodium dodecyl sulfate Analytical procedure (SDS), 100 mg/mL denatured salmon sperm DNA, and 50% (vol/vol) formamide. The membranes were hybrid-All values were expressed as mean Ϯ SD. The data were analyzed for homogeneity using Bartlett's test. The ized with 10 6 cpm/mL cDNA probes (described later in this article) in hybridization buffer (same as the prehy-statistical significance of any intergroup differences was determined using Dunnett's test for homogeneous data bridization buffer) for 24 hours at 42ЊC. After hybridization, the filters were washed three times for 15 minutes or Kruskal-Wallis test followed by Dunnett's type test for heterogenous data. Statistically significant differences in 1 ϫ standard sodium citrate (SSC; 20 ϫ SSC ϭ 3 mol/L NaCl, 0.3 mol/L sodium citrate, pH 7.0) with 0.1% between groups were defined as P values of less than 0.05. SDS at 60ЊC. The membranes were then autoradiographed with the intensifying screens (Du Pont, Wil-RESULTS mington, DE, USA) at Ϫ70ЊC for one to three days. The Summary of the pilot study density of the bands was quantitated with the computing densitometer Image Quant (Molecular Dynamics, Sun-Standard mouse chow containing different amounts of fluvastain (0.002% and 0.02%) was given to mice, and nyvale, CA, USA).
The following 32 P multiprime-labeled DNA probes were daily food consumption was measured for one cage (6 mice). The body weight of each mouse was measured prepared by a rediprime DNA labeling system (Amersham, Buckinghamshire, UK). Rat HO-1 cDNA (pRHO-1) was every day. The average daily food consumption was 5.5 Ϯ 0.8 g for vehicle-treated UUO mice, 5.4 Ϯ 0.7 g for low-kindly provided by Dr. Shibahara (Tohoku University School of Medicine, Sendai, Japan) [19] . ApaI/EcoRI dose fluvastatin-treated UUO mice, and 5.0 Ϯ 0.7 g for high-dose fluvastatin-treated UUO mice. The average fragment of pRHO-1 (649 bp) was used as a probe for Northern blotting. Rat glyceraldehyde-3-phosphate-dehy-body weight for each group was approximately 22 g for vehicle and low-dose fluvastatin-treated mice and ap-drogenase (GAPDH) cDNA [20] was used to monitor the variation of sample loading. proximately 20 g for high-dose fluvastatin-treated mice 10 days after commencing drug administration. The cal-Measurement of serum lipids culated dose was approximately 5 mg/kg/day for the lowdose fluvastatin-treated group and approximately 50 mg/ Fasting vein blood sample was collected from each mouse just before nephrectomy. Serum levels of total kg/day for high-dose treated mice. Based on these measurements, we defined the fluvastatin doses of the first cholesterol, triglyceride, were determined by using commercially available enzymatic methods (EIKEN Chemi-experiment as 5 and 50 mg/kg/day. Fluvastatin administration was started three days before the UUO operation cal Co., Tokyo, Japan).
and was continued to the day of sacrifice at 10 postopera-Morphometric analysis of the interstitial fibrosis in tive days (N ϭ 6 for each group, each time point). The Masson's trichrome or immunohistochemically stained ␣-SMA-positive area was quantitatively analyzed to exsections by a computer-aided manipulator plore possible effects of fluvastatin on the interstitial myofibroblast expansion. We found a dose-dependent The area of the fibrotic lesion in the cortical interstitium was determined on sections stained by Masson's decrease in ␣-SMA-positive area in fluvastatin-treated animals (vehicle 25.5 Ϯ 3.7, fluvastatin 5 mg/kg 19.5 Ϯ trichrome method to stain the collagen fibers (stained in light blue) as already described [7] . The interstitial area 5.0, P ϭ NS vs. vehicle; fluvastatin 50 mg/kg 15.7 Ϯ 1.9, P Ͻ 0.01 vs. vehicle). positive for immunohistochemical detection was analyzed and quantitated as described [21] . Under high-power
Based on the results of the preliminary experiment, we chose two doses of fluvastatin, 10 and 40 mg/kg/day, magnification (ϫ400), five randomly selected nonoverlapping fields from the cortical region were analyzed.
for the treatment of interstitial fibrosis in UUO. In addition, we decided to test the effect of pravastatin, an The fibrotic areas stained in light blue in the interstitium and tubular basement membrane or immunostaining HMG-CoA reductase inhibitor lacking in vitro antioxidant activity. positive area in the interstitium stained in brown were picked up on the digital images using a computer-aided
The second experiment used the body weight of individual mice just before sacrifice to monitor the differ-manipulator (image-operating computer program, Mac- 
Effects of fluvastatin on interstitial expansion of UUO kidneys
The representative appearance of Masson's trichromestained sections of obstructed kidneys from four experimental groups 10 days after ureteral obstruction is shown in Figure 1 . Interstitial expansion of obstructed kidneys was prominent in vehicle-treated animals and was also observed to a similar extent in pravastatin-treated animals. In fluvastatin-treated animals, interstitial expansion was less compared with vehicle-treated animals. Quantitative analysis of interstitial fibrosis area in four stitial expansion of UUO kidneys. There seemed to be less tubular atrophy in the cortex in the fluvastatintreated mice compared with vehicle or pravastatin-treated mice at 10 days after ureteral obstruction. ences in terms of food consumption (that is, test compound consumption). The average body weight 10 days Effects of fluvastatin on interstitial ␣-SMA expression after UUO was 22.6 Ϯ 0.9 g for vehicle, 22.0 Ϯ 0.3 g for in UUO kidneys fluvastatin 10, 20.7 Ϯ 1.1 g for fluvastatin 40, and 22.2 Ϯ Induction of interstitial myofibroblasts was assessed 0.8 g for pravastatin 10. There was a slight decrease in by immunohistochemical detection of ␣-SMA. shows the representative appearance of ␣-SMA immunowas already noticed in the preliminary experiment. No reactivity in the interstitium of UUO kidneys 10 days after difference in body weight was observed among vehicle-or ureteral obstruction. Intense immunostaining of ␣-SMA fluvastatin 10-or pravastatin 10-treated mice, suggesting was observed in the periglomerular and peritubular interthat a similar amount of fluvastatin and pravastatin was stitium in addition to the vascular smooth muscle of the administered in fluvastatin 10-and pravastatin 10-treated mice.
arterioles in vehicle-treated mouse kidneys 10 days after ureteral ligation (Fig. 3A) . No interstitial immunostaining (10 and 40 mg/kg/day) significantly reduced the ␣-SMA immunostaining at 10 days after ureteral obstruction. of ␣-SMA was detected in the contralateral unobstructed or sham-operated kidneys (data not shown). Fluvastatin Expression of heme oxygenase-1 in the but not pravastatin treatment reduced the appearance obstructed kidneys of ␣-SMA-positive myofibroblasts in the interstitium (Fig. 3B-D) . Quantitative analysis of ␣-SMA immuno-In our previous study, there was an induction of HO-1 mRNA expression as early as 12 hours after the onset of staining is shown in Figure 4 . Fluvastatin at both doses tion was examined by Northern blot analysis. As shown in Figure 5 , there was a significant reduction in HO-1 mRNA levels in the high-dose fluvastatin-treated group. Figure 6 shows the representative appearance of the im- noreactivity was observed in the periglomerular and per-Prava 10; pravastatin (10 mg/kg/day)-treated group. itubular interstitium of the obstructed kidneys from vehicle-treated mouse (Fig. 6A) . AGE immunostaining was reduced in fluvastatin-treated animals but not in pravas-DISCUSSION tatin-treated animals (Fig. 6B) at both low (10 mg/kg/ day; Fig. 6C ) and high (40 mg/kg/day; Fig. 6D ) doses.
The possible involvement of oxidative stress in the pathogenesis of obstructive nephropathy has recently be-Quantitative analysis of AGE immunostaining in interstitium is shown (Fig. 7) . A significant reduction in the gun to attract attention. We have recently revealed increased oxidative stress in the interstitium of obstructed AGE-positive area was observed in fluvastatin-treated mouse kidneys.
kidneys by the increased immunostaining of CML at 10 days after ureteral obstruction and an early up-regula-Effects of fluvastatin and pravastatin on serum lipids tion of HO-1 mRNA expression [12] . The present study levels in UUO mice tested the therapeutic value of fluvastatin, an HMG CoA reductase inhibitor, as a potential antioxidant agent tar-Serum cholesterol or triglyceride levels were not affected by fluvastatin or pravastatin treatment at 10 days geting increased oxidative stress and fibrosis in the tubulointerstitium of UUO kidneys. after ureteral obstruction (Table 1 ). This observation is consistent with the previous recognition that HMG-CoA
The major finding in this study is the reduction of oxidative stress in the interstitium of obstructed kidneys reductase inhibitors have little lipid-lowering effect in mice [22] . from mice treated by fluvastatin. Of note, the effect was observed in the absence of the lipid-lowering effect of the compound. This is the first demonstration of in vivo antioxidant activity of fluvastatin toward kidney. Two different doses were tested, and both high and low doses were revealed to be effective in reducing the accumulation of AGE in the interstitium of the obstructed kidneys.
Fluvastatin was shown to have in vitro antioxidant activity against oxidative modification of low-density lipoprotein [16]. Yamamoto, Hoshi, and Ichihara investigated the effect of fluvastatin and pravastatin on the lipid peroxidation in vitro and found that the order of magnitude of inhibition was butylated hydroxytoluene Ͼ probucol Ն fluvastatin Ͼ pravastatin, with 0.3 mol/L, 8.2 mol/L, superoxide radicals and hydrogen peroxide [23]. This may explain the different effects between fluvastatin and pravastatin on the accumulation of AGE in the obstructed kidneys. Tubulointerstitial injury is an invariant finding in the We found that fluvastatin but not pravastatin has a chronically diseased kidney, irrespective of the type of suppressive effect on the interstitial expansion and interdisease or the compartment in which the disease origistitial expression of ␣-SMA in the obstructed kidneys.
nates. Recent investigations revealed a close association The therapeutic efficacy of HMG-CoA reductase inhibibetween the interstitial damage and the prognosis of tors in renal diseases has been shown in experimental renal dysfunction [27, 28] . The mechanisms of the develsettings. Yoshimura et al found in rat anti-Thy 1.1 gloopment of tubulointerstitial injury and interstitial fibrosis merulonephritis that simvastatin suppressed glomerular in UUO kidney are a complex pathophysiological sequel expression of ␣-SMA and glomerular hypercellularity of cellular and molecular events. The appearance of [24] . More recently, Kim, Han, and Lee demonstrated ␣-SMA-positive activated interstitial cells is one of the that lovastatin administration in streptozotocin-induced early changes leading to a consequent fibrosis in tubudiabetic rats significantly suppressed the increase in urine lointerstitium. Recent findings demonstrated that the enalbumin excretion, kidney weight, glomerular volume, hanced expression of ␣-SMA is a marker of interstitial and TGF-␤ mRNA expression [25] . They also found in phenotypic change in various forms of renal disease, and cultured mesangial cells that lovastatin suppressed the these activated interstitial cells are called "myofibrohigh glucose-induced up-regulation of TGF-␤ and fibroblasts" [29] . The appearance of myofibroblasts has also nectin mRNA. These studies were focused on the globeen considered to play a key role in the progression of merular lesion. Our study is the first demonstration, to renal fibrosis in both glomerular and interstitial lesions, our knowledge, of the therapeutic efficacy of HMG-CoA and to predict a progressive decline in renal function in reductase inhibitor toward tubulointerstitial lesion. In patients with several glomerulonephritis [30] [31] [32] [33] . Myocontrast to earlier studies, we did not find significant fibroblasts are also described in experimental renal damsuppression of the tubulointerstitial lesion in pravastatinages [11, 34] . A better understanding of the molecular treated animals. Pravastatin did not affect the appearmechanism of myofibroblast formation would give a new ance of myofibroblast assessed by ␣-SMA immunostaintherapeutic option targeting glomerular and tubulointering or increased oxidative stress in the interstitium restitial fibrosis. To date, little is known about the molecuvealed by HO-1 expression or AGE immunostaining. It lar mechanism of oxidative stress in the formation of was previously reported that an in vivo inhibitory effect myofibroblasts and consequent fibrotic lesion in the kidof pravastatin and fluvastatin on de novo cholesterol ney. Our previous and present studies showed the possisynthesis is comparable in rat kidneys when administered ble involvement of oxidative stress in the pathogenesis of orally at a dose of 12.5 mg/kg [26] . Our study suggests interstitial fibrosis in UUO [12] . Modification of proteins that the differential effect on interstitial fibrosis of fluand lipids by oxidative stress is believed to play a central vastatin and pravastatin cannot be attributed to the biorole in a variety of biological activities caused by increased oxidative stress such as cell proliferation [35] , availability of these drugs in the kidney in vivo. [39, 40] . It is tempting to establish the molecular link 
